Journal

Platelet-rich plasma: how long the effect lasts

How long platelet-rich plasma lasts and how often it is repeated depends on the indication and the patient. Here we explain how response is assessed.

Longevia MedicalOctober 27, 2026Leer en español

Platelet-rich plasma: how long the effect lasts, a question without a fixed answer

The first thing we want to make clear is this: how long platelet-rich plasma lasts is not a figure your physician can give you before knowing your case. The duration of the effect depends on the indication, the condition of the tissue, your individual biological response, and how advanced the problem being addressed is. There is no universal number because physiology does not work that way.

What we can explain clearly is why it varies, what the available evidence says about each indication, how a treatment response is assessed, and when repeating it makes sense. That is what you will find in this article.

What platelet-rich plasma is and why its duration is not fixed

Platelet-rich plasma, known as PRP, is obtained from a blood sample drawn from the patient. Centrifugation concentrates the platelets, which release growth factors upon activation. Those factors stimulate tissue repair processes in the area where they are applied.

The effect is not pharmacological in the classical sense: there is no external molecule with a defined half-life that the body eliminates in a predictable time. What occurs is a biological cascade. The duration of the effect depends on how long that regenerative signal persists and on the capacity of the tissue to respond to it. Both factors vary from person to person and from indication to indication.

Platelet-rich plasma is not a drug with a calculable half-life. It is a biological signal whose duration is defined by the tissue, not by the physician.

There are indications where the evidence is stronger and use is more widespread: tendon injuries, joint conditions, and cutaneous tissue regeneration. In each one, the behavior of the treatment is different.

Platelet-rich plasma in joints: when you see results and how long they persist

In the joint indication, the most studied use is in the knee with cartilage degeneration. The available evidence shows that some patients report functional improvement and pain reduction, but the magnitude and duration of that response are not uniform. Some people maintain the benefit for several months; in others, the effect is more modest or shorter-lived.

When you see results with platelet-rich plasma for joints is not a fixed date either. In general, the response is not immediate: the tissue needs time to activate the repair processes that the growth factors stimulate. Clinical follow-up is what allows us to identify whether there was a response, when it was most noticeable, and how long it is lasting.

What the evidence does not support is treating joint PRP as a replacement for surgery in advanced structural damage, or as an intervention that definitively halts disease progression. That remains under investigation and cannot be stated today.

Platelet-rich plasma in tendons: an indication with its own logic

Tendinopathy, especially in the Achilles tendon and the patellar tendon, is one of the indications where PRP has the longest clinical track record. Tendon tissue has low vascularization, which limits its capacity for spontaneous regeneration. The hypothesis is that a local concentration of growth factors can partially compensate for that limitation.

In this indication, how often platelet-rich plasma is performed depends on the response to the first cycle. Some protocols include a series of applications at defined intervals; others assess whether a response occurred before continuing. There is no single protocol because the clinical presentation varies: a long-standing chronic tendinopathy is not the same as a more recent injury with tissue that is still reactive.

In tendon, repeating without evaluating is not a protocol: it is a clinical decision that depends on what follow-up reveals.

Here, as in all indications, the relevant question is not how many sessions but whether the tissue is responding. That can only be answered through follow-up.

Platelet-rich plasma in skin: a different indication, with a different logic

In the skin context, PRP is used primarily to stimulate collagen production and improve skin texture. The best-documented indication is aging-related loss of skin density and, to a lesser extent, androgenic alopecia.

In skin, the question of how long platelet-rich plasma lasts has a clearer physiological answer: the collagen produced is real collagen, but aging continues. That means the result is not permanent by definition, not because the treatment fails, but because the biological process that motivated it does not stop.

For that reason, in this indication it is more common for the physician to propose maintenance sessions once the initial series has been completed and the response has been assessed. The frequency of those maintenance sessions, if they apply, is defined during follow-up, not at the start of treatment.

How often platelet-rich plasma is performed: the protocol is defined by the response

This is the question we are asked most often before starting a protocol. And the honest answer is that how often platelet-rich plasma is performed cannot be defined before seeing how the tissue responds to the first applications. A rigid schedule communicated at the outset is marketing, not medicine.

What can be described is the general clinical logic:

  • An initial series of applications is defined based on the indication and the condition of the tissue.
  • Between sessions, the physician assesses whether there are signs of response: changes in pain, in functionality, or in the objective parameters that have been established.
  • With that information, a decision is made to continue, space out, modify the protocol, or stop.
  • If there is no response after the initial series, repeating it has no clinical justification.

That last point matters: when it is not worth repeating is a decision as relevant as when it is. Tissue that has shown no sign of response after a complete series most likely needs a different approach, not more sessions of the same treatment.

flowchart TD
    A["Initial assessment: indication, tissue condition, objectives"] --> B["Series of applications defined by the physician"]
    B --> C["Follow-up: are there signs of response?"]
    C --> D["Response present"]
    C --> E["No response"]
    D --> F["Continue, space out, or maintain according to progress"]
    E --> G["Review indication and consider a different approach"]
    F --> H["Long-term follow-up"]

How response is assessed: follow-up is not optional

Clinical follow-up is the only way to know whether platelet-rich plasma is working and how long its effect is lasting. Without a baseline parameter and a subsequent measurement, any statement about the outcome is speculation.

In general practice, follow-up includes the assessment of functional criteria (range of motion, pain level, quality of life), objective criteria where applicable (imaging, standardized physical tests), and the patient's own perception. None of those elements is sufficient on its own. The combination is what allows decisions to be made with clinical judgment.

At Longevia Medical, care begins with an assessment, in person or remote, and the plan is provided in writing with the follow-up criteria defined from the outset. When the patient returns to their city, medical supervision continues.

A protocol without follow-up is not a protocol: it is a series of sessions without an evaluation criterion.

What the evidence supports, what is under study, and what does not apply

Precision matters here, because PRP generates many expectations and not all the information available online distinguishes between what is accepted and what is speculative.

What is accepted in clinical practice: PRP has a reasonable safety profile when it is properly prepared and indicated, because it uses biological material from the patient. Its use in certain tendon injuries and some joint conditions is supported by clinical studies, although results vary among patients.

What remains under investigation: the standardization of preparation protocols, the optimal platelet concentration for each indication, and long-term effects in various tissues. Its combination with other regenerative therapies is also under study. These are active fields and the results are not yet conclusive.

What does not apply: PRP does not cure degenerative diseases, does not replace structural treatments when the damage requires them, and is not an appropriate intervention for every person or every joint. Candidacy is established during the assessment.

If during or after an application you experience sudden intense pain, changes in skin color at the treated site (white or violet skin), difficulty breathing, or any new neurological symptom, go to the emergency room immediately. Those symptoms cannot wait for a message to the clinic.

The assessment as a starting point: what to expect at Longevia Medical

At Longevia Medical, located in Puerto Cancún, the indication for platelet-rich plasma, like any other intervention, begins with an individual assessment. That assessment can be in person or remote, and its purpose is to establish whether PRP applies to your case, with what objectives, with what follow-up criteria, and under what conditions.

The plan is provided in writing. The protocol is built from that assessment, the number of sessions the case requires, and the subsequent follow-up. There are no predefined schemes because no two cases are alike.

For those who want to explore how evidence is evaluated in regenerative medicine, Mayo Clinic and MedlinePlus offer general patient information in accessible language.

Frequently asked questions about platelet-rich plasma

How long does the effect of platelet-rich plasma last?

There is no fixed duration. It depends on the indication, the condition of the tissue, and the individual response. In some people the benefit persists for several months; in others it is shorter. Clinical follow-up is what makes it possible to know in each case.

When do you see results from platelet-rich plasma?

The response is not immediate because PRP activates a biological repair cascade that takes time. The physician establishes from the outset which parameters will be assessed and at what point during follow-up the first signs of response are expected.

How often is platelet-rich plasma performed?

The frequency is defined by the treatment response, not by a fixed calendar. An initial series is established and assessed. If there is a response, the physician decides whether to continue or space out the sessions. If there is none, repeating without clinical justification is not warranted.

Is platelet-rich plasma appropriate for everyone?

No. Candidacy depends on the indication, the condition of the tissue, the patient's medical history, and the treatment objectives. That is established during the initial assessment, not beforehand. Not every joint, tendon, or skin condition has an indication for PRP.

Does platelet-rich plasma carry risks?

Because it uses biological material from the patient, the safety profile is reasonable when preparation and indication are correct. Even so, like any invasive procedure, it is not without the possibility of reactions. Medical supervision ahead of each session and in the days after is part of the protocol.

Begin privately

Tell us what you want to protect.

This first conversation is for orientation, not diagnosis. A coordinator will identify the right clinical pathway and explain the secure next step.

Request a private consultation↗

Book a private consultation

Tell us what you want to protect.

Choose a preferred date and time. A coordinator confirms your appointment by WhatsApp or email and explains the secure next step. This first conversation is for orientation, not diagnosis.

Do not include medical records or sensitive health information here.
Thank you. We received your request. A coordinator will confirm your appointment by WhatsApp or email.